drugset / Trial / NCT01552590

Effect of Samsca on Control of Hyponatremia and Extracellular Fluid in Cirrhotic Patients With Ascites

NCT01552590

Phase 4 Terminated 74 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
RandomizedParallel-groupSingle-blindTreatment

Summary

This study is to evaluate the efficacy of a 2-week course of tolvaptan in improving serum sodium and the excretion of extracellular fluid in liver cirrhotic patients with ascites and hyponatremia

Timeline

Start
2012-04
Primary completion
2012-04
Completion
2012-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Tolvaptan Small molecule

Indications

No indication recorded.